S-1: Anteris Technologies Global Corp. Files for U.S. IPO to Advance Heart Valve Technology

Anteris Technologies Global Corp., a structural heart company, has filed for an initial public offering (IPO) in the U.S. to support the development and commercialization of its innovative DurAVR transcatheter heart valve system.

Summary

• Anteris Technologies Global Corp. is seeking to raise capital through a U.S. IPO to fund the development of its DurAVR transcatheter heart valve (THV) system.
• The DurAVR THV system is a single-piece, biomimetic valve designed to improve blood flow for patients with aortic stenosis.
• The company's proprietary ADAPT tissue technology has shown clinical results of being calcium-free for up to 10 years.
• Anteris has completed an early feasibility study (EFS) with 15 patients and plans to submit an IDE for a pivotal trial to the FDA by Q1 2025.
• The global market for TAVR is estimated to reach $9.9 billion by 2028, with North America and Europe being key target markets.
• The company is currently generating small amounts of revenue and has incurred net losses since inception.
• The IPO will also facilitate a reorganization of Anteris Technologies Ltd, an Australian public company, into a Delaware corporation.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative aspects. The technology and market potential are promising, but the company faces significant financial and operational risks. The sentiment is neutral to slightly negative due to the going concern warning.

Positives

• The DurAVR THV system has a novel biomimetic design that aims to replicate the normal blood flow of a healthy human aortic valve.
• The company's ADAPT tissue has been clinically demonstrated to be calcium free for up to 10 years post-procedure.
• The ComASUR delivery system is designed to provide precise alignment with the hearts native commissures to achieve accurate placement of the DurAVR THV system.
• The company has observed promising results in relation to hemodynamics, laminar flow and exercise capacity in its FIH study.
• The company has received approval from the FDA to commence an EFS to treat 15 patients with severe aortic stenosis using the DurAVR THV system in up to seven heart valve centers across the United States.
• The company has a strong intellectual property position with 35 issued patents and over 50 pending patent applications.

Negatives

• The company has a history of operating losses and may not achieve or maintain profitability in the future.
• There is substantial doubt about the companys ability to continue as a going concern.
• The company will require substantial additional future financing and may be unable to raise sufficient capital.
• The company operates in a highly competitive and rapidly changing industry.
• The company relies on third parties to conduct its clinical trials and preclinical studies.
• The company is subject to various risks relating to international activities that could affect its profitability, including risks associated with currency fluctuations and changes in foreign currency exchange rates.

Risks

• The company may not be able to successfully identify, develop, obtain and maintain regulatory clearance or approval for and ultimately commercialize any of its current or future products.
• The company may find it difficult to enroll patients in its clinical trials, and patients could discontinue their participation in clinical trials, which could delay or prevent clinical trials and make those trials more expensive to undertake.
• The company could become exposed to product liability claims that could harm its business, and it may be unable to obtain insurance coverage at acceptable costs and adequate levels.
• The company could be exposed to significant liability claims if it is unable to obtain insurance at acceptable costs and adequate levels or otherwise protect itself against potential product liability claims.
• The market price and trading volume of the companys Common Stock may be volatile and may be affected by economic conditions beyond its control.
• An active trading market for the companys Common Stock may not develop and you may not be able to resell your shares of Common Stock at or above the public offering price, if at all.
• The company has identified material weaknesses in its internal control over financial reporting. If it fails to remediate these material weaknesses, or if it experiences additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting in the future, it may not be able to accurately or timely report its financial condition or results of operations.

Future Outlook

The company intends to test the features of the DurAVR THV system in a randomized global pivotal study against commercially approved TAVR devices. The design and scope of the Pivotal Trial will be finalized following completion of the company's submission to the FDA and receipt of feedback from the FDA. The purpose of the Pivotal Trial will be to demonstrate non-inferiority of the DurAVR THV system compared with commercially available TAVR systems for treatment of subjects with severe calcific aortic stenosis.

Management Comments

• The company clinically developed our DurAVR THV system over several years with significant physician input with the goal of addressing hemodynamic limitations of the current standard-of-care products.
• The company intends to test these features in the randomized global pivotal study (the Pivotal Trial) against commercially approved TAVR devices.

Industry Context

The company is entering a growing market for transcatheter aortic valve replacement (TAVR) procedures, which has seen significant year-over-year growth. The company aims to address the limitations of current TAVR devices with its novel biomimetic design and ADAPT tissue technology.

Comparison to Industry Standards

• The company's DurAVR THV system is designed to be a solution for all patients, including both older, less-active patients and younger patients, while previous generations of TAVRs were designed for older, high risk, less-active patients.
• The company's DurAVR THV system is a single-piece valve with a novel biomimetic design that aims to replicate the normal blood flow of a healthy human aortic valve as compared to traditional three-piece aortic valves.
• In the company's FIH study, they have observed promising results in relation to hemodynamics, laminar flow and exercise capacity, and when compared to a healthy aortic valve, the DurAVR THV system showed no significant difference in aortic flow.
• The company's ADAPT tissue has been clinically demonstrated to be calcium free for up to 10 years post-procedure, which is a significant improvement over traditional three-piece designs.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the IPO and the reorganization.
• Employees will be impacted by the changes in the company structure and the potential for changes in compensation and benefits.
• Customers may benefit from the development of the DurAVR THV system, which aims to improve outcomes for patients with aortic stenosis.
• Suppliers may be impacted by the companys reorganization and the potential for changes in supply chain management.
• Creditors may be impacted by the companys financial performance and ability to repay debts.

Next Steps

• The company plans to submit an IDE for the DurAVR THV system Pivotal Trial to the FDA by Q1 2025.
• The company anticipates enrollment to begin in the Pivotal Trial in the third quarter of 2025.
• The company expects that its CDIs will commence trading on the ASX on the trading day following the closing of this offering under the symbol AVR.

Key Dates

Keywords

transcatheter heart valve, aortic stenosis, TAVR, ADAPT tissue, biomimetic valve, medical device, structural heart, clinical trials, FDA approval, IPO